Celebrex Attorneys
Pfizer Finds Celebrex Heart
Attack Risk
NEW YORK - Pfizer Inc. said it has found an increased risk of heart attacks
with patients taking its top-selling painkiller Celebrex, a drug that
is in the same class as Vioxx, but has no plans to remove it from the
market.
Pfizer announced Friday that it found the increased risk in one of two
long-term cancer prevention trials, while the other trial showed no increased
risk.
The National Cancer Institute (news - web sites), which was conducting
the study for Pfizer, suspended the use of Celebrex after discovering
that patients taking 400mg to 800mg of the drug daily had a 2.5 times
greater risk of experiencing major heart problems than those who were
not. A separate cancer study found no increased heart risk with patients
taking 400mg of Celebrex per day.
Pfizer was conducting the trials as part of an effort to find a new application
for the drug.
The stock of the world's largest pharmaceutical maker plunged in morning
trading on the New York Stock Exchange (news - web sites), losing 14.6
percent, or $4.22, at $24.76 in heavy volume.
Both Celebrex and Vioxx, which is made by Merck & Co., are a type of
drug called cox-2 inhibitors, which have become popular because of their
effectiveness in treating the pain of arthritis and other ailments. Vioxx
was pulled from the market in September because of safety concerns.
Dr. Marie Griffin, an epidemiologist and drug safety expert at Vanderbilt
University, said the new findings on Celebrex is worrisome evidence suggesting
that all these cox-2 drugs have similar risks.
However, she noted that the halted study was testing an 400 to 800 milligram
dose ? four times the usual dose ? and that the safety problem with Celebrex
may only apply to those high levels.
"What this means for people who have heart disease is it's best to avoid
these drugs," she said.
For others, "people may want to reconsider their use of coxibs until
we feel better about their safety," and if they are using them, stick
to the normal dose, Griffin said.
Dr. Richard Hayes, a cardiologist in New York, said he would be recommending
that his patients taking Celebrex switch to nonprescription medicines
such as Advil to treat their pain.
"We thought Celebrex was safe and the problem was just with Vioxx," Hayes
said. "The problem is more complex than we thought."
Celebrex is the most-prescribed drug for treating arthritis. In the nine
months ending in September, worldwide sales of Celebrex more than doubled
from the same period a year earlier to $2.29 billion, accounting for 6
percent of Pfizer's total sales of $37.59 billion.
In releasing news of the study's findings, Pfizer chairman Henry McKinnell
said in a statement the company wanted to "rapidly communicate new information
to regulators, physicians and patients around the world."
The withdrawal of Vioxx has been a financial and public relations disaster
for Merck, in part because it has been accused of muzzling news about
the drug's side effects. Its legal liabilities are estimated at up to
$18 billion, and its shares have dropped by nearly one-third since the
recall announcement was made in late September.
Vioxx had been a blockbuster drug for Merck, it's No. 2 earner with annual
global sales of $2.5 billion, amounting to 11 percent of the company's
$22.49 billion in revenue last year. Some 2 million people worldwide had
been taking Vioxx.
Dr. Joseph Feczko, president of worldwide development for Pfizer, noted
that the results in the trial finding increased risk of heart attacks
were not consistent with either the other cancer prevention trial or with
a "large body of data" that the company had collected.
Earlier this month, the Food and Drug Administration (news - web sites)
said it was adding a warning to the labels of another Pfizer drug, Bextra,
noting a risk of potential heart problems associated with the use of Bextra
in people who have recently had heart bypass surgery. Bextra is also a
cox-2 inhibitor type of drug.
Griffin and two other Vanderbilt epidemiologists also raised fresh concerns
about Bextra, Pfizer's other cox-2, in a letter to be published Thursday
in the New England Journal of Medicine (news - web sites). Doctors should
not prescribe the drug "except in extraordinary circumstances," they recommend.
An Attorney For You is a free consumer service. We are
not a law firm. We help consumers find the best representation for their
legal needs. Our service allows the consumer to review responses by many
law firms. This process introduces competition amongst the law firms and
allows the consumer to find superior legal representation.
Fill out one simple form and get responses from Celebrex
attorneys competing for your case. Email up to 10 law
firms in one click; you review the responses in order to choose the right
attorney for you. | 
